DV
Dividend Vision

LXEO — Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock (LXEO)

Total return is -56.0% over the past 2.8 years, 142.4 points behind SPY at 86.4%. Its deepest 1-year drawdown was 61.1%.

Lexeo Therapeutics is a clinical-stage genetic medicine company developing gene therapy candidates to treat hereditary and acquired diseases, including friedreich ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, and APOE4-associated Alzheimer's disease. The company does not currently distribute dividends, as is typical for early-stage biotech firms focused on advancing their pipeline rather than generating current income. This security appeals primarily to investors with high risk tolerance seeking exposure to genetic medicine development rather than those focused on dividend income.

LXEO key facts

Asset type
Stock
Asset class
Equity
Inception date
11/02/2023
Last close
$4.84
Market cap
$357,273,440
Average volume
676670.0
Beta
1.427
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.09